drug · small molecule
LENALIDOMIDE
Marketedupdated 6mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 66 investigational indications.
targets
CRL4(CRBN) E3 ubiquitin ligase
all catalysts(2)
Trials studying LENALIDOMIDE
- phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- phase2A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- phase3A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- phase3A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- phase1A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- phase1A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 27, 2027
161 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Mar 8, 2028method-of-use (U-1983)US 87419291.3y
- Mar 8, 2028method-of-use (U-1983)US 87419291.3y
- Mar 8, 2028method-of-use (U-1983)US 87419291.3y
- Mar 8, 2028method-of-use (U-1983)US 87419291.3y
- Mar 8, 2028method-of-use (U-1983)US 87419291.3y
- Mar 8, 2028method-of-use (U-1983)US 87419291.3y
- Apr 27, 2027compositionUS 7465800161d
- Apr 27, 2027compositionUS 7465800161d
- Apr 27, 2027compositionUS 7465800161d
- Apr 27, 2027compositionUS 7465800161d
- Apr 27, 2027compositionUS 7465800161d
- Apr 27, 2027compositionUS 7465800161d
FDA exclusivities (12)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
- May 28, 2026ODE-241Orphan Drug (7y)
- May 28, 2026ODE-245Orphan Drug (7y)
News(10)
- At ASH, drugmakers to showcase early data for three-pronged cancer therapiesJ&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment for multiple myeloma.biopharma_dive · 11d ago
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 18d ago
- Biogen's monoclonal antibody felzartamab wins first global approval in ChinaBiogen’s monoclonal antibody felzartamab was approved in China for the treatment of multiple myeloma. Felzartamab will be available in China for second-line multiple myeloma patients alongside lena…endpoints · 3mo ago
- Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from CelgeneThe clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.biopharma_dive · 3mo ago
- BMS welcomes new multiple myeloma drug as generics batter current portfolioThe FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…biospace · 3mo ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 3mo ago
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysStrong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…biospace · 3mo ago
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.fiercebiotech · 3mo ago
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.biopharma_dive · 4mo ago
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.biopharma_dive · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that